The Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The hypothesis of this study is that pregabalin, 150 mg bid, will reduce general daytime pain
in patients diagnosed with diabetic peripheral neuropathy and that it will also reduce the
level of pain associated with walking. Consequently, it is hypothesized that the reduction in
pain will result in an increase in the amount of walking they do during the day, improvements
in their gait, balance, risk of falls and sleep patterns.